However, several preclinical studies have indicated that intrarenal RAS activity is much higher in type 2 diabetes than in type 1 diabetes.18 22 23 Therefore, we proposed a descriptive case study to examine the effect of SGLT2 inhibitors on urinary angiotensinogen excretion in patients with type 2 diabetes. The gene discussed is AGT; the disease is type 2 diabetes mellitus.